1.78

0.84% -0.015

Metagenomi Inc (MGX)

Overview News Price History Discussions Forecast

Metagenomi Inc stock is traded at $1.78, with a volume of 406.30K. It is down -0.84% in the last 24 hours and down -21.24% over the past month. Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Previous Close:

$1.795

Open:

$1.78

24h Volume:

406.30K

Relative Volume:

0.63

Market Cap:

$66.83M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+1.71%

1M Performance:

-21.24%

6M Performance:

+7.23%

1Y Performance:

-3.78%

1-Day Range:

$1.73

$1.82

1-Week Range:

$1.54

$1.83

52-Week Range:

$1.23

$4.92

Metagenomi Inc Stock (MGX) Company Profile

Name

Metagenomi Inc

Sector

Healthcare (1133)

Industry

Biotechnology (634)

Phone

(510) 871-4880

Address

5959 HORTON STREET, EMERYVILLE

Employee

124

Twitter

Next Earnings Date

Latest SEC Filings

MGX's Discussions on Twitter

Compare MGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MGX Metagenomi Inc	1.78	67.21M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	455.48	116.04B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	718.36	75.97B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	458.12	61.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	901.17	56.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.00	43.73B	447.02M	-1.18B	-906.14M	-6.1812

Metagenomi Inc Stock (MGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Initiated	H.C. Wainwright	Buy
May-02-24	Downgrade	JP Morgan	Overweight → Neutral
Mar-05-24	Initiated	BMO Capital Markets	Outperform
Mar-05-24	Initiated	Chardan Capital Markets	Buy
Mar-05-24	Initiated	JP Morgan	Overweight
Mar-05-24	Initiated	Jefferies	Buy
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	Wells Fargo	Overweight

View All

Metagenomi Inc Stock (MGX) Latest News

Dec 02, 2025

Will Metagenomi Inc. stock deliver consistent dividendsBull Run & Technical Pattern Based Signals - Newser

Dec 02, 2025

Pura Vida Investments LLC Grows Stock Position in Metagenomi, Inc. $MGX - MarketBeat

Dec 02, 2025

Metagenomi’s general counsel Wein sells $360 in stock By Investing.com - Investing.com Nigeria

Dec 02, 2025

Dec 01, 2025

Thomas Brian C. sells Metagenomi (MGX) shares worth $4888 By Investing.com - Investing.com Canada

Dec 01, 2025

Irish Jian, Metagenomi CEO, sells $2899 in MGX stock By Investing.com - Investing.com Canada

Dec 01, 2025

Metagenomi CFO Wapnick sells $2852 in shares By Investing.com - Investing.com Canada

Dec 01, 2025

Metagenomi (Nasdaq: MGX) to unveil APOC3 preclinical data from Ionis collaboration at 2025 Nature conference - Stock Titan

Dec 01, 2025

Nov 29, 2025

Why analysts upgrade Metagenomi Inc. stock2025 Technical Overview & Free Real-Time Market Sentiment Alerts - BỘ NỘI VỤ

Nov 29, 2025

Will Metagenomi Inc. stock attract ESG investorsQuarterly Earnings Report & Reliable Intraday Trade Plans - BỘ NỘI VỤ

Nov 29, 2025

Nov 28, 2025